The dependence of solid tumors on the formation of new vessels has led to the development and application of various anti‐angiogenesis agents such as bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), which has improved the oncologic outcome of patients with metastatic and advanced CRC [13]. The gene discussed is VEGFA; the disease is colorectal carcinoma.